Nonmalignant Hematologic Disorders

Expert faculty review and share their insights and perspectives on key findings in nonmalignant hematologic disorders presented at the 2022 ASH Annual Meeting.

Share

Program Content

Activities

  • Hematology 2022: Nonmalignant diseases
    Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2022
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 23, 2023

    Expires: March 22, 2024

Activities

XTEND-1 Pain Outcomes
XTEND-1: Analysis of Pain Scores in Phase III Study of Efanesoctocog Alfa Prophylaxis for Patients With Previously Treated Hemophilia A
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

Vemircopan in Untreated PNH
Phase II Trial of Vemircopan (ALXN2050) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

ADVANCE IV: Efgartigimod in ITP
ADVANCE IV: Phase III Trial of IV Efgartigimod in Adults With Primary Immune Thrombocytopenia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2022

Expires: December 13, 2023

CADENZA: PRO Outcomes
CADENZA: Patient-Reported and Quality-of-Life Outcomes From Phase III Study of Sutimlimab vs Placebo in Patients With Cold Agglutinin Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

ATLAS-PPX HRQoL
ATLAS-PPX: Health-Related Quality of Life With Fitusiran Prophylaxis in Patients With Hemophilia A or B With or Without Inhibitors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

REACH4: Ruxolitinib in Pediatric aGVHD
REACH4: Phase I/II Study of Ruxolitinib in Pediatric Patients With Untreated or Steroid-Refractory Acute Graft-vs-Host Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

APPLY-PNH: Iptacopan for PNH
APPLY-PNH: Phase III Trial of Iptacopan Monotherapy in Patients With Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia With Anti-C5 Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

BMT CTN 1703: PTCy + TAC + MMF for GVHD
BMT CTN 1703: Phase III Trial of PTCy + TAC + MMF vs TAC + MTX for Prevention of GVHD Following Reduced-Intensity Conditioning AlloSCT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

Faculty

cover img faculity

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

cover img faculity

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

cover img faculity

Marshall Mazepa, MD

Assistant Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

cover img faculity

Allison P Wheeler, MD, MSCI

Director of Research at Washington Center for Bleeding Disorders
Associate Professor, University of Washington School of Medicine
Division of Pediatric Hematology/Oncology & Division of Hematology and Oncology
Seattle, Washington

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen